Does T3 thyroid hormone signaling support hepatic LDL receptor expression and LDL clearance?

Physiology of T3-Mediated LDL Receptor Regulation

The active thyroid hormone, triiodothyronine ($T_3$), is a fundamental regulator of hepatic cholesterol metabolism and systemic lipid clearance. It primarily coordinates the expression of hepatic low-density lipoprotein receptors (LDLR), which are responsible for clearing atherogenic apolipoprotein B (apoB)-containing particles from the circulation.

• Direct Transcriptional Activation: $T_3$ binds directly to thyroid hormone receptors (TRs, predominantly the TR$\beta$ isoform in the liver). The $T_3$-TR complex binds to thyroid hormone response elements (TREs) located within the promoter region of the LDLR gene, directly upregulating its transcription.
• Indirect SREBP-2 Pathway: In addition to direct promoter binding, $T_3$ stimulates the transcription, translation, and nuclear translocation of sterol regulatory element-binding protein-2 (SREBP-2). SREBP-2 is the master transcription factor for cholesterol homeostasis, which binds to the sterol regulatory element (SRE) on the LDLR promoter, further amplifying receptor synthesis.
• Receptor-Mediated Endocytosis: Increased density of hepatic LDLRs accelerates the binding, internalization, and subsequent lysosomal degradation of circulating LDL particles, thereby lowering plasma LDL-cholesterol (LDL-C).

Pathophysiology of Low Free T3 and Impeared LDL Clearance

When circulating free $T_3$ (fT3) levels are deficient, this highly coordinated clearance mechanism is severely compromised:

• Decreased Receptor Density: A reduction in fT3 signaling directly translates to decreased SREBP-2 activity and diminished LDLR gene transcription. The resulting reduction in hepatocyte surface LDLR density significantly limits the liver's capacity to bind and internalize LDL.
• Reduced Fractional Catabolic Rate (FCR): Kinetic studies demonstrate that thyroid hormone deficiency significantly prolongs the half-life of circulating LDL by decreasing its FCR. Because the clearance rate is low, LDL particles remain in the bloodstream longer, increasing their susceptibility to pro-atherogenic modifications such as oxidation.
• Compounding Factors (TSH and PCSK9): In states of primary thyroid failure where low fT3 is accompanied by elevated thyroid-stimulating hormone (TSH), TSH independently upregulates proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 binds to LDLRs on the hepatocyte membrane and targets them for intracellular degradation, further reducing available receptor numbers and exacerbating hypercholesterolemia.

Clinical Implications

This pathophysiological relationship is highly relevant across several clinical scenarios:

• Hypothyroidism: Both overt and subclinical hypothyroidism are classic causes of secondary hypercholesterolemia characterized by elevated LDL-C and apoB.
• Non-Thyroidal Illness Syndrome (NTIS): Often seen in critical illness, chronic disease, or severe caloric restriction, the "low $T_3$ syndrome" can present with an atherogenic lipid profile partly driven by the down-regulation of these hepatic clearance pathways.

Bottom line

Ample biochemical, kinetic, and clinical evidence supports the claim. Triiodothyronine ($T_3$) signaling directly and indirectly (via SREBP-2) upregulates hepatic LDL receptor expression. Consequently, low free $T_3$ levels lead to decreased LDLR density, a reduced fractional catabolic rate of LDL, and impaired clearance of circulating LDL cholesterol.